T cells and immune checkpoint markers are enriched at the tumor margin in comparison with the tumor center, and Carapeto et al. suggested that high PD-1 or CD4-inducible T cell costimulatory factors in lymphocyte-activated tumor centers contribute to poor survival in patients with ICC 51. Here, CD4 is linked to neoplasm.